New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
16:14 EDTCYCCCyclacel Pharmaceuticals reports Q2 EPS (22c), consensus (30c)
Reports cash and cash equivalents totaled $33.5M as of June 30. The company said, "We are pleased to report that we have enrolled over 70% of the required number of patients in our Phase 3 SEAMLESS trial in front-line AML. At present we have approximately 90 study centers open for enrollment in the US and Europe with additional sites to be added. We expect to complete SEAMLESS enrollment around the end of 2014 with data readout in the second half of 2015. Having surpassed enrollment of 300 patients, we expect the study's Data Safety Monitoring Board to perform the fourth periodic safety review once 60 days of follow-up have been observed."
News For CYCC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2014
07:10 EDTCYCCCyclacel announces DSMB recommendation to continue Sapacitabine Phase 3 trial
Cyclacel Pharmaceuticals announced that the independent Data and Safety Monitoring Board, or DSMB, for the company's Phase 3 SEAMLESS study in acute myeloid leukemia, or AML, has completed its fourth planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available data from 317 randomized patients with at least 60 days of follow-up and noted that no safety or efficacy concerns were identified.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use